Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages

  Kyou Kwon, Jong ^a   Kim, Soon Ja ^b   Hoon Kim, Jung ^c   Mee Lee, Kyung ^a   Ho Chang, In ^a  

^a Chung Ang University College of Medicine   (South Korea)

^b Chung Ang University   (South Korea)

^c Korea Electric Power Research Institute (KEPRI)   (South Korea)

Author keywords

Bladder; Cancer; EIF4E; MTOR; Rapamycin; S6K1

Indexed keywords

INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6K1; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION;

BLADDER; CANCER; EIF4E; MTOR; RAPAMYCIN; S6K1;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84890800773     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.08.005     Document Type: Article

References (30)

1. Cookson M.S., Herr H.W., Zhang Z.F., et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997, 158(1):62-67.
2. Black P.C., Brown G.A., Grossman H.B., et al. Neoadjuvant chemotherapy for bladder cancer. World J Urol 2006, 24(5):531-542.
3. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23(21):4602-4608.
4. Wong K.K., Engelman J.A., Cantley L.C. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010, 20(1):87-90.
5. Isotani S., Hara K., Tokunaga C., et al. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem 1999, 274(48):34493-34498.
6. Jefferies H.B., Fumagalli S., Dennis P.B., et al. Rapamycin suppresses 5' TOP mRNA translation through inhibition of p70s6k. EMBO J 1997, 16(12):3693-3704.
7. Seager C.M., Puzio-Kuter A.M., Patel T., et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila) 2009, 2(12):1008-1014.
8. Seront E., Rottey S., Sautois B., et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012, 23(10):2663-2670.
9. Wu X., Obata T., Khan Q., et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004, 93(1):143-150.
10. Park S.J., Lee T.J., Chang I.H. Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study. Korean J Urol 2011, 52(7):466-473.
11. Schultz L., Albadine R., Hicks J., et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 2010, 116(23):5517-5526.
12. Foster D.A., Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009, 8(7):1026-1029.
13. Choo A.Y., Yoon S.O., Kim S.G., et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008, 105(45):17414-17419.
14. Chapuis N., Tamburini J., Green A.S., et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010, 16(22):5424-5435.
15. Willett M., Cowan J.L., Vlasak M., et al. Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1. Cell Signal 2009, 21(10):1504-1512.
16. Thoreen C.C., Kang S.A., Chang J.W., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009, 284(12):8023-8032.
17. Carracedo A., Ma L., Teruya-Feldstein J., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118(9):3065-3074.
18. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10(5):307-318.
19. Castellano E., Downward J. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol 2010, 346:143-169.
20. Nawroth R., Stellwagen F., Schulz W.A., et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 2011, 6(11):e27509.
21. Makhlin I., Zhang J., Long C.J., et al. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2011, 108(2 Pt 2):E84-E90.
22. Graff J.R., Zimmer S.G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003, 20(3):265-273.
23. Graff J.R., Konicek B.W., Carter J.H., et al. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008, 68(3):631-634.
24. Armengol G., Rojo F., Castellvi J., et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007, 67(16):7551-7555.
25. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12(1):9-22.
26. Pinto-Leite R., Botelho P., Ribeiro E., et al. Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res 2009, 28:3.
27. Fitzpatrick J.M., West A.B., Butler M.R., et al. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 1986, 135(5):920-922.
28. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: progression and recurrence. J Urol 1983, 130(6):1083-1086.
29. Bohle A., Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003, 170(3):964-969.
30. Luan F.L., Hojo M., Maluccio M., et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002, 73(10):1565-1572.